Theme

IP Group

IPOFinancial Services
60.95GBX
1.58%
Market Cap
545.27M
Volume
4.59M
146% of avg
P/E Ratio
3.10
EPS (TTM)
19.65
Beta
1.44
Day Range
58.97p - 61.70p
52 Week Range
34.35p60.95p62.50p
60.95p

Upcoming Events

Q1 2026
Results Release (Q1 2026)
High Impact Event
Mid 2026
OXCCU's second demonstration plant, OX2, to be fully operational
High Impact Event
March 17, 2026
Expected date for full year 2025 results announcement
High Impact Event
Late 2027
Target for delivering over £250m of exits
High Impact Event
IPO
NEUTRAL

IP Group Plc Announces Change in Shareholding

The asset management firm has disclosed a change in shareholding by Lombard Odier Asset Management (Europe) Limited.

IPO
NEUTRAL

IP Group Provides Update on Potential Royalties from Metsera Obesity Drugs

The investment firm updates on its potential future royalty income from a portfolio of obesity drug candidates being developed by Metsera, which was recently acquired by Pfizer.

IPO
NEUTRAL

IP Group's portfolio company Monolith acquired by CoreWeave

The technology investor announces the sale of one of its portfolio companies, Monolith, to a US-based AI firm.

IPO
VERY GOOD

IP Group's portfolio company OXCCU raises £20.75m in Series B funding

The cleantech company has raised £20.75m in Series B funding to scale its sustainable aviation fuel technology, attracting investment from major industry players.

IPO
BAD

IP Group Reports £43m Loss in H1 2025 Amid Challenging Market Conditions

The venture capital firm reported a £43m loss for H1 2025, showing some improvement but facing ongoing challenges in a difficult market environment for early-stage investments.

IPO
NEUTRAL

IP Group Plc Announces Holding Change

The asset manager has announced a change in its major shareholding, with the Railways Pension Trustee Company Limited increasing its stake in the company.

IPO
NEUTRAL

IP Group Provides Notice of Upcoming Results

The investment firm announces it will publish its half-year results and host an investor presentation next month.

IPO
NEUTRAL

IP Group Announces Promising Tissue Repair Data from Portfolio Company Istesso

The biotechnology company announces ground-breaking data from its portfolio company Istesso, showing the potential of its investigational medicines to elicit tissue repair in various chronic conditions.

IPO
NEUTRAL

IP Group Provides Update on Share Buyback Program

The investment firm provides an update on its share buyback program, extending the program by £20 million.

IPO
NEUTRAL

IP Group Announces Regulatory Notification

The asset manager has disclosed a change in its shareholding position in the company.